PreferredStockChannel

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Thu, December 2, 6:21 PM

Slide #58. XOMA Corporation Preferred Stock Offering

Company: XOMA Corporation (NASDAQ:XOMA)
Date announced: 12/10/2020
Shares Offered: 880,000
Date of Pricing: 12/10/2020
Price Per Share: $25.00
Preferred Stock Offering Details: XOMA Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the "Preferred Stock"). The Company expects to grant the underwriters a 30-day option to purchase additional shares of the Preferred Stock in connection with the offering. -updated 12/10- XOMA Corporation (Nasdaq: XOMA) (XOMA or the Company) today announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the Preferred Stock) at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 104,000 shares of Preferred Stock. The offering is expected to close on or about December 15, 2020, subject to customary closing conditions.

XOMA is a biotech royalty aggregator. Co. has a pipeline of monoclonal antibodies and technologies available to license to pharmaceutical and biotechnology companies, including: PTH1R program, which is an anti-parathyroid receptor pipeline that includes functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, which is an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients, reducing the advancement to a number of insulin injections needed to control their blood glucose levels; and X213, which is an allosteric inhibitor of prolactin action.
Open the XOMA Page at Preferred Stock Channel »

Name: 
XOMA Corp
Website: 
www.xoma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding XOMA: 
16 (see which ones)
Total Market Value Held by ETFs: 
$22,855,426.84
Total Market Capitalization: 
$232,000,000
% of Market Cap. Held by ETFs: 
9.85%
 

Open the XOMA Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree XOMA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.33 out of 4)
40th percentile
(ranked lower than approx. 60% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 58 of 573 | www.PreferredStockChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.